The process of evaluating the in vivo efficacy of non-peptidyl receptor ant
agonists in animal models is frequently complicated by failure of compounds
displaying high affinity against the human receptors to show measurable af
finity at the corresponding rodent receptors. In order to generate a suitab
le animal model in which to evaluate the in vivo activity of non-peptidyl g
lucagon receptor antagonists, we have utilized a direct targeting approach
to replace the murine glucagon receptor with the human glucagon receptor ge
ne by homologous recombination. Specific expression of the human glucagon r
eceptor (GR) in the livers of transgenic mice was confirmed with an RNase p
rotection assay, and the pharmacology of the human GRs expressed in the liv
ers of these mice parallels that of human GR in a recombinant CHO cell line
with respect to both binding of I-125-glucagon and the ability of glucagon
to stimulate cAMP production. L-168,049, a non-peptidyl GR antagonist sele
ctive for the human GR shows a 3.5 fold higher affinity for liver membrane
preparations of human GR expressing mice (IC50 = 172 +/- 98 nM) in the pres
ence of MgCl2 in marked contrast to the measured affinity of the murine rec
eptor (IC50 = 611 +/- 97 nM) for this non-peptidyl antagonist. The human re
ceptors expressed are functional as measured by the ability of glucagon to
stimulate cAMP production and the selectivity of this antagonist for the hu
man receptor is further verified by its ability to block glucagon-stimulate
d cyclase activity with 5 fold higher potency (IC50 = 97.2 +/- 13.9 nM) tha
n for the murine receptor (IC50 = 504 +/- 247 nM). Thus we have developed a
novel animal model for evaluating GR antagonists in vivo. These mice offer
the advantage that the regulatory sequences which direct tissue specific a
nd temporal expression of the GR have been unaltered and thus expression of
the human gene in these mice remains in the normal chromosomal context.